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Introduction: The effectiveness of corticosteroid therapy on the mortality of acute respiratory distress syndrome
(ARDS) remains under debate. We aimed to explore the grounds for the inconsistent results in previous studies and
update the evidence.
Methods: We searched MEDLINE, Cochrane Central Register of Controlled Trials and Web of Science up to
December 2013. Eligible studies included randomized clinical trials (RCTs) and cohort studies that reported mortality
and that had corticosteroid nonusers for comparison. The effect of corticosteroids on ARDS mortality was assessed
by relative risk (RR) and risk difference (RD) for ICU, hospital, and 60-day mortality using a random-effects model.
Results: Eight RCTs and 10 cohort studies were included for analysis. In RCTs, corticosteroids had a possible but
statistically insignificant effect on ICU mortality (RD, −0.28; 95% confidence interval (CI), −0.53 to −0.03 and RR, 0.55;
95% CI, 0.24 to 1.25) but no effect on 60-day mortality (RD, −0.01; 95% CI, −0.12 to 0.10 and RR, 0.97; 95% CI, 0.75 to
1.26). In cohort studies, corticosteroids had no effect on ICU mortality (RR, 1.05; 95% CI, 0.74 to 1.49) but non-significantly
increased 60-day mortality (RR, 1.30; 95% CI, 0.96 to 1.78). In the subgroup analysis by ARDS etiology, corticosteroids
significantly increased mortality in influenza-related ARDS (three cohort studies, RR, 2.45, 95% CI, 1.40 to 4.27).
Conclusions: The effects of corticosteroids on the mortality of ARDS differed by duration of outcome measures and
etiologies. Corticosteroids did not improve longer-term outcomes and may cause harm in certain subgroups. Current
data do not support routine use of corticosteroids in ARDS. More clinical trials are needed to specify the favorable and
unfavorable subgroups for corticosteroid therapy.Introduction
Despite advances in critical care medicine over the past
decades, the mortality rate for acute respiratory distress
syndrome (ARDS) remains high [1-3]. Because dysregu-
lated inflammation is the cardinal feature of ARDS [2,4],
systemic corticosteroids have been considered a poten-
tially beneficial therapy. However, previous randomized
trials have failed to provide convincing evidence to prove
the efficacy of corticosteroids in decreasing the mortality
of ARDS [5-8]. Only secondary outcomes, such as oxy-
genation improvement and reduction of the duration of
mechanical ventilation, have shown consistent findings
in favor of corticosteroid therapy.* Correspondence: hsienho@gmail.com
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unless otherwise stated.Published meta-analyses about corticosteroid therapy
for ARDS reported inconsistent conclusions [9-13]. Dif-
ferent study selections and heterogeneity on mortality
endpoints and etiologies of ARDS may account for the
inconsistent study results in previous meta-analyses.
Measuring the treatment effects at short-term or longer-
term follow-up may influence study results, because thera-
peutic effects of corticosteroids develop early but some
adverse effects, such as infection, develop late. Using
short-term outcome as the study endpoint may under-
estimate the risk of corticosteroid therapy and overesti-
mate the overall benefit. In addition, the mechanisms
of lung injury and fibroproliferative response to injury
vary in pulmonary and extrapulmonary ARDS [14].
Therefore, the treatment response to corticosteroids in
ARDS may be different in ARDS of different etiologies.
However, the influence of the etiologies of ARDS ond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in previous studies.
We conducted a systematic review and meta-analysis of
corticosteroid therapy in ARDS with the aim of updating




This systematic review was conducted using an a priori
published protocol submitted to the PROSPERO website
(Registration No.: CRD42012002583) and reported accord-
ing to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) criteria [15]. No institutional
review board (IRB) approval or consents were needed
for this systematic review because it evaluated published
studies. We searched MEDLINE via the NCBI Entrez
system, Cochrane Central Register of Controlled Trials
(CENTRAL) and Web of Science (WOS) up to December
2013. We also screened the bibliographies of retrieved
studies and recent review articles to identify additional
trials.
Keyword search was performed in MEDLINE, CEN-
TRAL and WOS using the following terms: ‘corticosteroids’
AND (‘ALI’ OR ‘acute lung injury’ OR ‘ARDS’ OR ‘acute
respiratory distress syndrome’). The search was then
limited to human studies. We also used MeSH term search
in MEDLINE with the following terms: (‘respiratory distress
syndrome, adult’ OR ‘acute lung injury’) AND (‘hydroxycor-
ticosteroids’ OR ‘glucocorticoids’). No language restrictions
were applied.
The inclusion criteria included randomized controlled
trial (RCT) and cohort study designs that reported
mortality outcomes and had corticosteroid nonusers
for comparison.
Quality assessment and data extraction
Two investigators (SYR and CTH) independently extracted
data from the included studies into standardized data
recording forms. Quality assessment of these studies
was done using the Cochrane Risk of Bias Tool for
RCTs and the Newcastle-Ottawa Quality Assessment
Scale for cohort studies [16,17].
Outcome measurement
The primary study endpoint was all-cause mortality. Dif-
ferent mortality measures were reported in the studies,
including ICU mortality, hospital mortality and 60-day
mortality. According to the duration of mean ICU and
hospital stay reported in the included studies [7,8,18], we
classified ICU mortality as short-term outcome, hospital
mortality as a mid-term outcome, and 60-day mortality
as a longer-term outcome. Additionally, two studies re-
ported 14-day and 45-day mortality [5,19], and thesetwo outcome measures were classified as ICU mortality
and 60-day mortality, respectively. The secondary study
endpoint was nosocomial infections related to cortico-
steroid therapy.
Statistical analysis
Relative risk (RR) and risk difference (RD) were used as
measurements of association. Outcome measures were
pooled using a random-effects model because of antici-
pated heterogeneity among included studies. We treated
risk ratio and hazard ratio as RR when pooling across
studies. We estimated the point estimate and 95% confi-
dence interval (95% CI) of the summary effect estimate
(RR or RD). RCTs and cohort studies were analyzed
separately. When one arm of a study contained no
events, 0.5 was added to all cells of the two-by-two
table. Heterogeneity was explored using the Q statistic
and I2. Heterogeneity was considered low, moderate,
and high by I2 values of 25%, 50%, and 75%, respectively
[20]. We hypothesized that the treatment response to
corticosteroids in ARDS patients may vary by different
mortality endpoints, by different etiologies of ARDS, and
by different timing for starting treatment. We, therefore,
conducted subgroup analyses to explore whether the treat-
ment response varied by these variables of interest. All
tests were two-sided and P values of <0.05 were deemed
significant. The data were analyzed using Stata software,
V.11 (StataCorp).
Results
We identified 1,771 citations from the search of electronic
databases. Using the predefined inclusion and exclusion
criteria (Figure 1), seven RCTs [5-8,19,21,22], one post-hoc
analysis of RCT [23], and 10 cohort studies were included
for evaluation [18,24-32]. The post-hoc analysis was classi-
fied as RCT for the analysis. Of the eight RCTs, three trials
studied preventive rather than therapeutic use of cortico-
steroids in ARDS. A total of 1,474 subjects were analyzed,
including 725 from RCTs and 749 from cohort studies.
The details of the included studies are summarized in
Additional file 1: e-Table S1. Quality assessment of the
included studies suggested a low risk of bias in most RCTs
(Additional file 1: e-Table S2) but the comparability and
representativeness of the study patients were concerns in
cohort studies (Additional file 1: e-Table S3, e-Table S4).
Mortality outcomes
Figure 2 shows the effects of corticosteroid therapy on
mortality. Pooled results from all RCTs suggested that
corticosteroids had no significant effect on mortality
(RR, 0.91; 95% C.I., 0.71 to 1.18). Visual inspection of the
forest plot and the estimated I2 (57%) revealed moderate
heterogeneity among the included studies. To explore the




Web of Science (454)
1603 Citations screened by 
bibliography
1031 Excluded for nonhuman studies, 
reviews, case reports or unrelated 
study purposes 
572 Abstracts or full-text articles assessed 
for eligibility
554 Excluded with reasons
Unrelated studies (493)
Not RCTs or cohort studies (16) 
Full text not available (20) 
No non-users of steroids (11)
No report of ARDS mortality (14)18 Studies included in narrative 
synthesis
18 Studies included in quantitative synthesis 
(meta-analysis)
168 Duplicates  excluded
Figure 1 Number of studies evaluated at each stage of the systematic review.
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The results suggested that corticosteroids had a possible
but statistically insignificant effect on short-term (ICU)
mortality (RR, 0.55; 95% CI, 0.24 to 1.25 and RD, −0.28;
95% CI, −0.53 to −0.03) but did not decrease 60-day
mortality. Within-study observations in those studies
reporting two mortality outcomes by different follow-up
durations also suggested similar findings, that the disad-
vantage of corticosteroid therapy increased by prolonging
the follow-up period (Additional file 1: e-Table S5). In
cohort studies, corticosteroids had no effect on ICU
mortality but there was a trend of increased mortality
on 60-day mortality (Table 1). A funnel plot of standard
error versus risk ratio for mortality did not suggest sig-
nificant publication bias (Additional file 2: e-Figure S1,
e-Figure S2).
Etiologies of ARDS
We also conducted a subgroup analysis by different etiolo-
gies of ARDS. For this analysis, we classified the study
population into four groups: unselected ARDS, sepsis-
related ARDS (infection-related ARDS >70% of cases),
influenza-related ARDS, and post-operative ARDS. Table 2
summarizes the treatment outcome of corticosteroids
in these four groups of ARDS patients. The responses
to corticosteroid therapy differed among different eti-
ologies of ARDS. Notably, corticosteroids significantly
increased mortality in influenza-related ARDS (RR, 2.44;95% CI, 1.4 to 4.27). One cohort study reported good
treatment outcome in patients with post-operative ARDS
but the sample size was very small [29].
Infection risk of corticosteroids
The definitions and observational durations of infectious
complications varied greatly among included studies
(Additional file 1: e-Table S6). The observed durations of
infectious complications ranged from 7 days to 28 days.
Pooled data showed conflicting findings that corticoste-
roids tend to increase infection risk in cohort studies
(risk ratio, 1.35, 95% CI, 0.99 to 1.84) but decrease infec-
tion risk in RCTs (risk ratio, 0.83, 95% CI, 0.65 to 1.06)
(Figure 3).
Discussion
Our study found that the mortality outcomes of cortico-
steroid therapy in ARDS differed by duration of outcome
measures. Corticosteroids had a possible but statistically
insignificant effect on short-term mortality in RCTs but
did not decrease longer-term mortality in either RCTs or
cohort studies (Table 1). Within-study observation in
studies reporting two mortality endpoints also suggested
that the benefit of corticosteroid therapy decreased when
follow-up was prolonged [7,8,23]. This raises a concern
that corticosteroid therapy in ARDS may bring initial
benefits by suppressing the inflammatory process and
reducing alveolocapillary permeability [4,33,34], but the
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Figure 2 Effect of corticosteroids on hospital or 60-day mortality.
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onset of adverse effects, such as immunosuppression
and altered tissue repair [35,36]. We also found that the
effect of corticosteroid therapy differed among different
populations of ARDS patients. Corticosteroids may causeTable 1 Short-term and longer-term effects of corticosteroids
Mortality endpoints Number of
Studies Patients Effe
Randomized controlled trialsa
ICU mortality 3 292 0.
Hospital mortality 2 201 0.
60-day mortality 2 279 0.
Cohort studies
ICU mortality 5 226 1.
Hospital mortality 4 317 1.
60-day mortality 2 264 1.
aTrials testing preventive therapy of corticosteroids for acute respiratory distress syn
and longer-term mortality. For cohort studies, only pooled relative risk was provideharm in certain ARDS subgroups, such as influenza-
related ARDS. Taken together, current data do not support
routine use of corticosteroids in ARDS. Given the hetero-
geneous nature of ARDS and the pleiotropic effects of
corticosteroids, more clinical trials are needed to specifyon mortality
Relative risk Risk difference
ct size (95% CI) I2 Effect size (95% CI) I2
55 (0.24 to 1.25) 75% −0.28 (−0.53 to −0.03)* 76%
49 (0.12 to 2.07) 77% −0.26 (−0.65 to 0.13) 75%
97 (0.75 to 1.26) 0% −0.01 (−0.12 to 0.10) 0%
05 (0.74 to 1.49) 1% Not calculable -
00 (0.23 to 4.34) 75% Not calculable -
30 (0.96 to 1.78) 0% Not calculable -
drome (ARDS) were excluded. Some studies provided data on both short-term
d because adjusted results were needed for data pooling *P-value <0.05.
Table 2 Effects of corticosteroids on mortality in different etiologies of ARDS
Etiology of ARDSa Number of studies Number of patients Relative risk (95% CI) I2
Unselected ARDS
Randomized controlled trials 3 370 0.88 (0.65 to 1.18) 28%
Cohort studies 4 238 1.12 (0.78 to 1.60) 40%
Influenza-related ARDSb
Cohort studies 3 283 2.45 (1.40 to 4.27) ** 0%
Sepsis-related ARDS
Randomized controlled trials 2 201 0.50 (0.12 to 2.02) 76%
Cohort studies 2 208 1.04 (0.58 to 1.85) 0%
Post-operative ARDSb
Cohort studies 1 20 0.10 (0.01 to 0.63) * -
aExcludes the studies of preventive use of corticosteroids; bno randomized controlled trials available. *P-value <0.05. ** P-value <0.005. ARDS, acute respiratory
distress syndrome.
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therapy. For more comprehensive assessment of the
effects of corticosteroid therapy, future studies should
evaluate a mortality endpoint of adequate duration and
the 60-day mortality used by the ARDSnet appears to











































Figure 3 Effect of corticosteroids on infectious complications.Our study demonstrated the diverse treatment effects
of corticosteroids among different etiologies of ARDS
(Table 2). It is biologically plausible that different etiolo-
gies of ARDS have different responses to corticosteroid
therapy because the pulmonary fibroproliferative response
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in ARDS caused by different etiologies [37,38]. Therefore,
it is not surprising that the efficacy of corticosteroid ther-
apy differs among different etiologies. Additionally, our
analysis showed that corticosteroids significantly increased
mortality in influenza-related ARDS. The poorer outcome
may be attributed to prolonged viral shedding and an
increased risk of superinfection [39,40]. An expert review
also advised against use of corticosteroids in the manage-
ment of H1N1 influenza A infection [41].
The dosage and timing of corticosteroid therapy in
ARDS has changed over the last decades. Based on the
equivalent doses of methylprednisolone, studies before
1990 usually used a high daily dose (30 mg/kg) and short
period (≤2 days) regimen to prevent or treat ARDS. In
the following two decades, most studies used a protocol
of daily dose of ≤2 mg/kg with a gradual taper. Some
investigators suggested different treatment dosages for
early ARDS and persistent ARDS in which a duration of
ARDS ≤3 days was considered as early ARDS and ≥5 days
as persistent or unresolving ARDS [4]. The treatment dose
was suggested to be ≤1 mg/Kg for early ARDS [7,23], and
2 mg/Kg for persistent ARDS [6,8]. We summarized the
treatment outcomes of corticosteroid therapy initiated
at different stages of ARDS (Table 3). Our analysis
found that patients with persistent ARDS seemed more
likely to benefit from corticosteroid therapy. In addition,
the subgroup analysis of the ARDSnet steroid study sug-
gested against starting corticosteroid therapy >14 days
after the onset of ARDS [6]. These findings suggest a
subgroup of ARDS might benefit most from corticoster-
oid therapy: persistent ARDS with the onset of ARDS <14
days. Persistent ARDS indicates a specific subgroup or
phenotype of ARDS that is characterized by exaggerated
or unresolving lung inflammation [4]. In this subgroup,
the benefit of corticosteroid therapy may outweigh the
treatment risk. Dosage and administration schedules may
also affect treatment outcomes of corticosteroids. How-
ever, it was difficult to evaluate the effects of these two
factors in the study-level analysis. Cohort studies did
not use standardized treatment protocols and individual-Table 3 Subgroup analysis by timing of starting corticosteroi
Timing of starting steroids Number of studies
Preventive therapy
Randomized controlled trials 3
Early ARDS (≤3 days)
Randomized controlled trials 3
Cohort studies 4
Persistent ARDS (≥5 days)
Randomized controlled trials 2
Cohort studies 3
Three studies were excluded in this analysis due to no report of treatment timing.level data are needed to conduct such analyses. In RCTs,
therapeutic trials usually used a low-dose regimen (1 to
2 mg/kg/day) and similar administration schedules.
Published meta-analyses reached inconsistent conclu-
sions on the role of corticosteroids for ARDS [9-13]. We
summarize the study conclusions and study selection
strategy of previous meta-analyses in Table 4. Among
the included studies in these meta-analyses, an extremely
protective effect for corticosteroids was observed in the
two studies published by Meduri [7,8], but the effects were
neutral and modest in other trials. In addition, inclusion
or exclusion of trials of using corticosteroids in severe
pneumonia into analysis also had an impact on the re-
sults of meta-analysis. Confalonieri and Meduri reported
remarkable mortality reduction by corticosteroid therapy
in a severe pneumonia study [42]. Previous meta-analyses
reporting significant mortality reduction of corticosteroid
therapy usually included this pneumonia study [12,13].
However, a large cohort study using a registry database
reported that low-dose corticosteroids were associated
with an increased mortality in pneumonia with septic
shock [43].
Systemic corticosteroid therapy may bring several un-
favorable side effects [36,44], and one major concern in
patients with ARDS is an increased risk of nosocomial
infection secondary to immunosuppression. Because symp-
toms and signs of early infection may be masked by corti-
costeroids, previous RCTs performed intensive infection
surveillance procedures during the study to reduce the
risk of superinfection [6,7]. However, these intensive
surveillance procedures are not always performed out-
side of clinical studies. Our analysis showed that the
infection risks reported in RCTs and cohort studies were
conflicting (Figure 3). It is not known whether restrictive
patient selection and infection surveillance procedures in
RCTs played a role in making such a difference. Similar to
the concern for mortality outcomes, the infection risk of
corticosteroid therapy should be evaluated in an adequate
time frame because the immunosuppressive effect may
develop late in the clinical course. However, most studies
evaluated infectious complications in a short durationd therapy
Number of patients Relative risk (95% CI) I2
154 1.24 (0.57 to 2.72) 80%
367 0.86 (0.71 to 1.04) 17%
303 1.00 (0.24 to 4.20) 70%
204 0.52 (0.11 to 2.52) 79%
105 0.73 (0.44 to 1.23) 0%
Table 4 Comparisons of published meta-analyses
Study (Ref.) Included studies Summary of study conclusion Additional remarks
Adhikari et al.
(2004) [9]
Three RCTs Early high-dose corticosteroids had no effect
on early mortality. Corticosteroids given for
late phase ARDS reduced hospital mortality.
Study interest not focused on corticosteroids;
few studies and small sample size.
Agarwal et al.
(2007) [10]
Four RCTs and two
cohort studies
Current evidence does not support a role for
corticosteroids in the management of ARDS in
either the early or late stages of the disease.





Nine RCTs (eight RCTs for
mortality analysis)
A definitive role of corticosteroids in the
treatment of ARDS in adults is not established.
Including the RCTs of preventive use of
corticosteroids; excluding pneumonia
studies; using Bayesian random effects
models for data pooling.
Tang et al.
(2009) [12]
Four RCTs (three ARDS studies
and one pneumonia study) and
five cohort studies
The use of low-dose corticosteroids was
associated with improved mortality and morbidity
outcomes without increased adverse reactions.
Including a RCT of pneumonia; excluding
studies of high-dose and preventive use
of corticosteroids.
Lamontagne
et al. (2010) [13]
Twelve RCTs (six ARDS studies
and six pneumonia studies)
Corticosteroids administered within 14 days of
disease onset may reduce all-cause mortality.
Including six studies of pneumonia.
ARDS, acute respiratory distress syndrome; RCTs, randomized controlled trials.
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corticosteroid therapy might, therefore, be underestimated.
External validity should be noted for this meta-analysis.
Included individual RCTs reported numerous exclusion
criteria for patient enrollment. The results of this meta-
analysis should not be generalized to patients with par-
ticular comorbidities. Most RCTs excluded patients with
underlying diseases that might benefit from corticoste-
roids, such as inflammatory airway diseases or vasculitis.
Were these patients enrolled, the study outcome might be
more likely to favor the corticosteroid group. On the other
hand, clinical trials also excluded patients with conditions
that militate against the use of corticosteroids, such as
active gastrointestinal bleeding, disseminated infections,
extensive burns or immunocompromised status. Outside
the scope of the generalizability of current data, the use of
corticosteroids in ARDS should be individually evaluated.
Underlying diseases are important considerations to justify
the use of corticosteroids.
Strengths and limitations
The strengths of our study include a comprehensive
search strategy to include all studies analyzed in previous
meta-analyses but not be restricted to these studies and
to evaluate short-term and longer-term outcomes of
corticosteroid therapy. The diversity of treatment outcomes
among different etiologies of ARDS was also evaluated.
These analyses help explore the causes of inconsistency
among previous meta-analyses and achieve a more
concrete suggestion for the use of corticosteroids in
ARDS. With inclusion of the data from cohort studies,
the disparity between clinical trials and real-world
practice was disclosed, and their consistent results or trends
helped to increase the robustness of this meta-analysis.
In addition, we performed a sensitivity analysis to test
the influence of study pooling strategy, an analysis that
previous meta-analyses did not perform. Our study alsohas limitations. The number of RCTs and sample size
were relatively small. There are only two studies in
some subgroup analyses and underpower is a concern.
Sparse data are another concern for data pooling by the
random-effects model. With respect to the evaluation of
an etiology-specific response to corticosteroids, the classi-
fication of ARDS etiologies was limited because the mix of
study populations was diverse among several studies.
Finally, study quality might be a confounding factor that
we were unable to control in the subgroup analysis when
we try to explore the association between follow-up
duration and mortality. Earlier studies tend to be of poor
quality and their follow-up duration was also shorter.
Conclusions
ARDS is a heterogeneous disease with various etiologies
and clinical courses. The effects of corticosteroids on ARDS
were inconsistent in previous studies due to different out-
come measures and study populations. This study shows
that corticosteroids do not improve longer-term outcomes
and may cause harm in certain subgroups of ARDS, such
as influenza-related ARDS. Based on current available
data, we do not suggest routine use of corticosteroids for
ARDS. More clinical trials are needed to improve the
overall quality of evidence and to specify the unfavorable
and favorable subgroups of ARDS for corticosteroid ther-
apy. Future studies should evaluate short-term as well
as longer-term outcomes for comprehensive evaluation
of the treatment efficacy of corticosteroids in ARDS.
Key messages
 ARDS is a heterogeneous disease with various
etiologies and clinical courses. The effects of
corticosteroids on ARDS were inconsistent in
previous studies due to different outcome measures
and study populations.
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longer-term effects of corticosteroids on ARDS
mortality. Pooled data showed that corticosteroid
therapy did not decrease longer-term mortality.
 The effectiveness of corticosteroid therapy differed
in different etiologies of ARDS. Corticosteroids
might cause harm in certain subgroups of ARDS
patients, such as influenza-related ARDS.
 Current data do not support routine use of
corticosteroids for ARDS. More clinical trials are
needed to improve the overall quality of evidence and
to specify the unfavorable and favorable subgroups of
ARDS patients for corticosteroid therapy.
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